Alto Neuroscience, Inc. (ANRO) stock
Close on Nov 11, 2026Market cap $1.22BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.22B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.12
- Dividend yield
- –
- Free cash flow yield
- -6.52%
Fundamentals
- Net income
- -$95.18M
- EPS, diluted
- -$2.46
- Free cash flow
- -$79.68M
- Book value per share
- $6.37
- Diluted shares
- 47M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $28.61
- Open
- $29.75
- Day's range
- $28.88 – $31.30
- Volume
- 1,221,967
- Average volume (20 days)
- 574,742
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.87
- 52-week range
- $10.80 – $37.48
- RSI (14 days)
- 71.1
- Volatility (1 year)
- 77.7%
- Relative volume
- 2.17×
- WACC
- 14.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANRO | S&P 500 | Difference | ANRO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.8% | -2.4% | +30.2 pts | ||
| 3 months | +8.2% | -1.2% | +9.4 pts | ||
| Year to date | +75.0% | +12.3% | +62.7 pts | ||
| 1 year | +132.5% | +12.4% | +120.0 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alto Neuroscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
About Alto Neuroscience
Pharmaceutical Preparations
Alto is a clinical-stage biopharmaceutical company that develops targeted therapies for neuropsychiatric conditions. The company utilizes a proprietary precision psychiatry platform that evaluates brain-based biomarkers through electroencephalography, neurocognitive assessments, wearable technology, and genomic data to identify patients likely to benefit from specific interventions. Its clinical development pipeline comprises seven assets, including ALTO-207, ALTO-300, ALTO-100, ALTO-101, and ALTO-203, targeting disorders such as major depressive disorder, bipolar depression, treatment-resistant depression, cognitive impairment associated with schizophrenia, and Parkinson’s disease. Its products are developed for individuals diagnosed with psychiatric and neurological disorders.
Company profile, executives and historyAlto Neuroscience stock: common questions
What is Alto Neuroscience's stock price?
ANRO closed at $31.15 on Nov 11, 2026, up 8.88% on the day. Over the past 52 weeks it traded between $10.80 and $37.48.
What is Alto Neuroscience's market cap?
Alto Neuroscience was worth $1.22B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ANRO's P/E ratio?
Alto Neuroscience lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.46), so it has no meaningful P/E ratio.
Does Alto Neuroscience pay a dividend?
No. Alto Neuroscience has not paid a cash dividend over the last twelve months.
When does Alto Neuroscience report earnings next?
Alto Neuroscience is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ANRO stock performed over the past year?
Including dividends, ANRO returned +132.5% over the past year, against +12.4% for the S&P 500.
How many ANRO shares are sold short?
6M shares were sold short at the latest FINRA report, 15.34% of the float, or 10.5 days of average trading volume.
Who are Alto Neuroscience's competitors?
Companies most similar to Alto Neuroscience by business, industry and size include XENE, CMPS, NERV, MPLT, ANVS.
See a number that looks wrong?